Drugs and drug combinations with activity against influenza virus in clinical development or evaluation
| Drug . | Drug target . | Manufacturer/sponsor . | Route of administration . | Clinical development stage . | Emergency use mechanism available . |
|---|---|---|---|---|---|
| Peramivir | Viral neuraminidase | Biocryst Pharmaceuticals | IV, IM | Phase 3 | EUA |
| Zanamivir | Viral neuraminidase | GlaxoSmithKline | IV | Phase 2 | Emergency use program |
| Oseltamivir | Viral neuraminidase | Roche Pharmaceuticals | IV | Phase 1 | No |
| T-705 (Favipiravir) | Viral polymerase | Toyama Chemical | Oral | Phase 2 (US), phase 3 (Japan) | No |
| CS-8958 (R-118958) | Viral neuraminidase | Daiichi Sankyo Co, Ltd | Inhaled | Phase 3 | No |
| DAS181 | Sialic acid receptor of the respiratory epithelial cells | Nexbio Inc | Inhaled | Phase 2 | No |
| Nitazoxanide | Viral hemaglutinin | Romark Laboratories | Oral | In vitro; no animal or human data | Licensed for treatment of cryptosporidiosis (no indication for influenza treatment) |
| Neuraminidase inhibitor + amantidine + ribavirin | In vitro synergistic combination targeting viral neuraminidase, M2 and depletion of intracellular phosphate of influenza | Adamas Pharmaceuticals | Oral | Phases 2-3 | Licensed drugs (no indication for combination) |
| Oseltamivir + zanamivir | Viral neuraminidase | GlaxoSmithKline Roche Pharmaceuticals | Oral and inhaled | Phases 3-4 | Licensed drugs (no indication for combination) |
| Drug . | Drug target . | Manufacturer/sponsor . | Route of administration . | Clinical development stage . | Emergency use mechanism available . |
|---|---|---|---|---|---|
| Peramivir | Viral neuraminidase | Biocryst Pharmaceuticals | IV, IM | Phase 3 | EUA |
| Zanamivir | Viral neuraminidase | GlaxoSmithKline | IV | Phase 2 | Emergency use program |
| Oseltamivir | Viral neuraminidase | Roche Pharmaceuticals | IV | Phase 1 | No |
| T-705 (Favipiravir) | Viral polymerase | Toyama Chemical | Oral | Phase 2 (US), phase 3 (Japan) | No |
| CS-8958 (R-118958) | Viral neuraminidase | Daiichi Sankyo Co, Ltd | Inhaled | Phase 3 | No |
| DAS181 | Sialic acid receptor of the respiratory epithelial cells | Nexbio Inc | Inhaled | Phase 2 | No |
| Nitazoxanide | Viral hemaglutinin | Romark Laboratories | Oral | In vitro; no animal or human data | Licensed for treatment of cryptosporidiosis (no indication for influenza treatment) |
| Neuraminidase inhibitor + amantidine + ribavirin | In vitro synergistic combination targeting viral neuraminidase, M2 and depletion of intracellular phosphate of influenza | Adamas Pharmaceuticals | Oral | Phases 2-3 | Licensed drugs (no indication for combination) |
| Oseltamivir + zanamivir | Viral neuraminidase | GlaxoSmithKline Roche Pharmaceuticals | Oral and inhaled | Phases 3-4 | Licensed drugs (no indication for combination) |
EUA indicates emergency use authorization granted by US Food and Drug Administration; and IM, intramuscular.